• Sciencebase.com on Facebook
  • Blogroll

Archive for May 29th, 2007

Comparing Prostate Drugs

Posted by David Bradley on May 29th, 2007

Prostate cancer drug docetaxelLast week, we revealed that lycopene from the red part of tomatoes is not quite the wonder preventative in prostate cancer we had been led to believe by ketchup manufacturers and fans of the Bloody Mary cocktail. So, thankfully, clinical trials for drugs to treat this lethal form of cancer is ongoing.

Recent research by oncologist Michael Krainer of the Medical University of Vienna, and colleagues has shown that the chemotherapy drug docetaxel is the best treatment available for androgen-independent prostate cancer.

The trial compared the efficacy of docetaxel and vinorelbine and found the former to reduce the risk of disease progression by more than 50% compared with vinorelbine.

The use of chemotherapy to treat prostate cancer has rapidly grown in importance over recent years, with several comprehensive clinical trials helping to drive forward progress. In two of these trials, the chemotherapy drug docetaxel offered patients a significantly improved prognosis. However, other clinical trials indicated that the drug vinorelbine, which like docetaxel acts on cellular microtubuli, also produces impressive results and it is often used as an alternative to docetaxel. These new results offer doctors valuable support in choosing the appropriate treatment for their patients.